Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

459 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
Toyota J, Karino Y, Suzuki F, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, Hu W, McPhee F, Linaberry M, Yin PD, Swenson ES, Kumada H. Toyota J, et al. Among authors: ikeda f. J Gastroenterol. 2017 Mar;52(3):385-395. doi: 10.1007/s00535-016-1245-6. Epub 2016 Aug 9. J Gastroenterol. 2017. PMID: 27502287 Clinical Trial.
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
Akuta N, Toyota J, Karino Y, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, McPhee F, Noviello S, Kumada H. Akuta N, et al. Among authors: ikeda f. J Gastroenterol. 2018 Sep;53(9):1089-1097. doi: 10.1007/s00535-018-1445-3. Epub 2018 Mar 2. J Gastroenterol. 2018. PMID: 29500489
Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.
Matsumoto A, Nishiguchi S, Enomoto H, Kang JH, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsuhashi H, Nagaoka S, Okuse C, Kagawa T, Mine T, Takaguchi K, Saito S, Hino K, Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, Murata K, Tanaka E. Matsumoto A, et al. Among authors: ikeda f. J Gastroenterol. 2018 Feb;53(2):247-257. doi: 10.1007/s00535-017-1360-z. Epub 2017 Jun 20. J Gastroenterol. 2018. PMID: 28634723 Clinical Trial.
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
Takehara T, Sakamoto N, Nishiguchi S, Ikeda F, Tatsumi T, Ueno Y, Yatsuhashi H, Takikawa Y, Kanda T, Sakamoto M, Tamori A, Mita E, Chayama K, Zhang G, De-Oertel S, Dvory-Sobol H, Matsuda T, Stamm LM, Brainard DM, Tanaka Y, Kurosaki M. Takehara T, et al. Among authors: ikeda f. J Gastroenterol. 2019 Jan;54(1):87-95. doi: 10.1007/s00535-018-1503-x. Epub 2018 Sep 10. J Gastroenterol. 2019. PMID: 30203225 Free PMC article. Clinical Trial.
Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B.
Matsumoto A, Nishiguchi S, Enomoto H, Tanaka Y, Shinkai N, Okuse C, Kang JH, Matsui T, Miyase S, Yatsuhashi H, Nagaoka S, Kanda T, Enomoto M, Yamada R, Hiramatsu N, Saito S, Takaguchi K, Ito K, Masaki T, Morihara D, Tsuge M, Chayama K, Ikeda F, Kagawa T, Kondo Y, Murata K, Tanaka E. Matsumoto A, et al. Among authors: ikeda f. J Gastroenterol. 2020 Oct;55(10):977-989. doi: 10.1007/s00535-020-01707-6. Epub 2020 Jul 14. J Gastroenterol. 2020. PMID: 32666202
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
Izumi N, Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, Toyoda H, Kakizaki S, Tanaka Y, Kawakami Y, Enomoto H, Ikeda F, Jiang D, De-Oertel S, McNabb BL, Camus G, Stamm LM, Brainard DM, McHutchison JG, Mochida S, Mizokami M. Izumi N, et al. Among authors: ikeda f. Hepatol Int. 2018 Jul;12(4):356-367. doi: 10.1007/s12072-018-9878-6. Epub 2018 Jul 20. Hepatol Int. 2018. PMID: 30030720 Free PMC article. Clinical Trial.
Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy.
Wada N, Ikeda F, Mori C, Takaguchi K, Fujioka SI, Kobashi H, Morimoto Y, Kariyama K, Sakaguchi K, Hashimoto N, Moriya A, Kawaguchi M, Miyatake H, Hagihara H, Kubota J, Takayama H, Takeuchi Y, Yasunaka T, Takaki A, Iwasaki Y, Okada H. Wada N, et al. Among authors: ikeda f. Acta Med Okayama. 2018 Aug;72(4):401-406. doi: 10.18926/AMO/56178. Acta Med Okayama. 2018. PMID: 30140089 Free article.
Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib.
Adachi T, Nouso K, Miyahara K, Oyama A, Wada N, Dohi C, Takeuchi Y, Yasunaka T, Onishi H, Ikeda F, Nakamura S, Shiraha H, Takaki A, Takabatake H, Fujioka SI, Kobashi H, Takuma Y, Iwadou S, Uematsu S, Takaguchi K, Hagihara H, Okada H; Okayama Liver Cancer Group. Adachi T, et al. Among authors: ikeda f. J Gastroenterol Hepatol. 2019 Jun;34(6):1081-1087. doi: 10.1111/jgh.14535. Epub 2018 Dec 10. J Gastroenterol Hepatol. 2019. PMID: 30402928
459 results